Avara CDMO bought healthcare facility from GSK

| By | API, CDMO, GlaxoSmithKline, Pharmaceutical Manufacturing

Avara Pharmaceutical Services, a world class contract development and manufacturing organization (CDMO) with an extensive network serving the global bio-pharmaceutical market, has signed an agreement with GSK to acquire a GSK consumer healthcare manufacturing facility in Aiken, South Carolina, USA.

The transaction is expected to complete on or before June 1, 2018.

“This acquisition is an important component of our strategic plan and expands our services by adding additional solid dose capability in the United States, which is in very high demand,” stated Timothy C. Tyson, Chairman and CEO. 

Avara Pharmaceutical Services is a state-of-the-art contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing and packaging of small molecule drugs, including highly potent compounds.  Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules. Avara also has sterile manufacturing capability.

Following completion of the transaction with GSK, Avara Pharmaceutical Services will have seven sites. Three in the US, including the corporate HQs; one in Puerto Rico, one in the UK, one in Ireland, and one in Italy.

SOURCE: avara
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.